Compare IHD & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IHD | SERA |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.5M | 77.2M |
| IPO Year | N/A | 2021 |
| Metric | IHD | SERA |
|---|---|---|
| Price | $6.52 | $1.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 156.7K | 24.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 10.32% | N/A |
| EPS Growth | N/A | ★ 14.66 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $77,000.00 |
| Revenue This Year | N/A | $25.84 |
| Revenue Next Year | N/A | $715.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.54 | $1.37 |
| 52 Week High | $7.28 | $4.24 |
| Indicator | IHD | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 38.49 | 29.24 |
| Support Level | $5.82 | $1.37 |
| Resistance Level | $7.19 | $2.00 |
| Average True Range (ATR) | 0.12 | 0.19 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 27.24 | 16.10 |
Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.